- Home
- HOND vs SGHT Comparison
HOND vs SGHT Comparison
Compare HOND & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOND
- SGHT
- Stock Information
- Founded
- HOND 2024
- SGHT 2011
- Country
- HOND United States
- SGHT United States
- Employees
- HOND N/A
- SGHT N/A
- Industry
- HOND
- SGHT Medical Specialities
- Sector
- HOND
- SGHT Health Care
- Exchange
- HOND NYSE
- SGHT Nasdaq
- Market Cap
- HOND 334.9M
- SGHT 179.7M
- IPO Year
- HOND 2024
- SGHT 2021
- Fundamental
- Price
- HOND $11.17
- SGHT $3.34
- Analyst Decision
- HOND
- SGHT Buy
- Analyst Count
- HOND 0
- SGHT 8
- Target Price
- HOND N/A
- SGHT $3.87
- AVG Volume (30 Days)
- HOND 331.5K
- SGHT 166.0K
- Earning Date
- HOND 01-01-0001
- SGHT 07-31-2025
- Dividend Yield
- HOND N/A
- SGHT N/A
- EPS Growth
- HOND N/A
- SGHT N/A
- EPS
- HOND 0.20
- SGHT N/A
- Revenue
- HOND N/A
- SGHT $78,109,000.00
- Revenue This Year
- HOND N/A
- SGHT N/A
- Revenue Next Year
- HOND N/A
- SGHT $11.22
- P/E Ratio
- HOND $54.48
- SGHT N/A
- Revenue Growth
- HOND N/A
- SGHT N/A
- 52 Week Low
- HOND $9.90
- SGHT $2.03
- 52 Week High
- HOND $12.24
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- HOND N/A
- SGHT 38.59
- Support Level
- HOND N/A
- SGHT $3.37
- Resistance Level
- HOND N/A
- SGHT $3.60
- Average True Range (ATR)
- HOND 0.00
- SGHT 0.25
- MACD
- HOND 0.00
- SGHT -0.10
- Stochastic Oscillator
- HOND 0.00
- SGHT 0.00
About HOND HCM II ACQUISITION CORP
HCM II Acquisition Corp is a blank check company.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.